See more : Fomento de Construcciones y Contratas, S.A. (FMOCF) Income Statement Analysis – Financial Results
Complete financial analysis of Protara Therapeutics, Inc. (TARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Far Vista Petroleum Corp. (FVSTA) Income Statement Analysis – Financial Results
- Sekisui House, Ltd. (1928.T) Income Statement Analysis – Financial Results
- Turquoise Hill Resources Ltd. (TRQ.TO) Income Statement Analysis – Financial Results
- Rogue Resources Inc. (GCRIF) Income Statement Analysis – Financial Results
- China Shipbuilding Industry Group Power Co., Ltd. (600482.SS) Income Statement Analysis – Financial Results
Protara Therapeutics, Inc. (TARA)
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.95M | 0.00 | 0.00 |
| Cost of Revenue | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 0.00 | 27.00K | 57.00K |
| Gross Profit | -341.00K | -247.00K | -1.17M | -196.00K | -16.00K | -115.00K | -148.00K | -123.00K | -57.00K | 2.95M | -27.00K | -57.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.99M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| General & Administrative | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 105.99K | 9.84M | 8.49M | 4.10M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.42M | -123.00K | -57.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.10M | 3.10M | 2.03M |
| Other Expenses | 0.00 | 29.52M | 0.00 | 0.00 | 0.00 | 207.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.10M | 7.94M |
| Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.71M | 20.87M | 10.53M | 7.12M | 8.00M |
| Interest Income | 2.73M | 1.11M | 237.00K | 466.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 20.00K |
| Interest Expense | 0.00 | 1.14M | 1.74M | 34.00K | 0.00 | 0.00 | 259.00K | 193.00K | 144.00K | 857.00K | 861.00K | 0.00 |
| Depreciation & Amortization | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 30.00K | 27.00K | 57.00K |
| EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.40M | -21.32M | -2.45M | -7.02M | -7.91M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -83.28% | 0.00% | 0.00% |
| Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.71M | -20.87M | -7.58M | -7.12M | -8.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -257.12% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.19M | 1.11M | 237.00K | 466.00K | 0.00 | 643.00K | 398.00K | 179.00K | -507.00K | 4.24M | -790.00K | 26.00K |
| Income Before Tax | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -117.00K | -466.00K | -262.00K | 5.35M | 657.00K | 372.00K | -363.00K | 5.10M | 0.00 | 0.00 |
| Net Income | -40.42M | -64.82M | -47.14M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| EPS | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS Diluted | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| Weighted Avg Shares Out | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
| Weighted Avg Shares Out (Dil) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2024 and provided...
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near...
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026 Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has reached alignment with the U.S. Food and Drug Administration...
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive data from three-month evaluable carcinoma in situ (CIS) patients treated across...
3 Stocks That Could Help You Retire on a Private Island
If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can't go the buy-and-hold approach that legendary investors like Warren Buffett deploy. For one thing, that was...
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended December 31,...
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th...
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced additional encouraging data from the Phase 1a dose-escalation component of its ongoing...
Source: https://incomestatements.info
Category: Stock Reports